Lowered DHCR7 activity measured by ergosterol conversion in multiple cell types in Smith-Lemli-Opitz syndrome

Sharon Ginat, Kevin P. Battaile, Brian C. Battaile, Cheryl Maslen, K. Michael Gibson, Robert D. Steiner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder of cholesterol metabolism characterized by multiple congenital anomalies and mental retardation. SLOS results from mutations in 7-dehydrocholesterol Δ 7 reductase (DHCR7), the gene encoding the final enzyme involved in cholesterol biosynthesis. The resulting cholesterol deficiency and excessive 7- and 8-dehydrocholesterol (7-DHC, 8-DHC) in plasma and tissues are almost always diagnostic for SLOS. We measured DHCR7 activity in fibroblasts, amniocytes, and chorionic villi from controls, heterozygotes, and SLOS subjects. The enzyme activity (expressed as percent conversion of substrate) was significantly lower in untransformed fibroblasts from SLOS subjects (4.47%±0.72) compared to untransformed fibroblasts from heterozygotes (26.6%±4.6, p <0.01) or controls (50.6%±5.3, p <0.001). We also measured plasma cholesterol and 7-DHC, determined the severity score and identified DHCR7 mutations for most of the subjects. There was no significant correlation of enzyme activity with severity score, plasma cholesterol level, plasma 7-DHC level, or the 7-DHC:cholesterol ratio. We conclude that even though enzyme activity as measured by the ergosterol assay may not correlate with severity, this assay has the potential to distinguish SLOS cells from carrier or unaffected cells in a variety of cell types, and should prove useful in confirming a diagnosis in atypical cases where sterol levels are equivocal. Additionally, it may be important to measure residual enzyme activity in SLOS subjects being considered for a trial of statins, as this treatment could theoretically be detrimental in subjects with little or no DHCR7 activity. Finally, the data suggest a threshold enzyme activity of 8% conversion, below which disease occurs.

Original languageEnglish (US)
Pages (from-to)175-183
Number of pages9
JournalMolecular Genetics and Metabolism
Volume83
Issue number1-2
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Smith-Lemli-Opitz Syndrome
Ergosterol
Oxidoreductases
Cholesterol
Enzyme activity
Enzymes
Fibroblasts
Heterozygote
Plasmas
Assays
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Chorionic Villi
Mutation
Sterols
7-dehydrocholesterol reductase
7-dehydrocholesterol
Intellectual Disability
Gene encoding
Biosynthesis
Metabolism

Keywords

  • Cholesterol
  • DHCR7
  • Diagnosis
  • Enzyme assay
  • Metabolic disorder
  • Metabolism
  • Severity score
  • Smith-Lemli-Opitz

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

Lowered DHCR7 activity measured by ergosterol conversion in multiple cell types in Smith-Lemli-Opitz syndrome. / Ginat, Sharon; Battaile, Kevin P.; Battaile, Brian C.; Maslen, Cheryl; Gibson, K. Michael; Steiner, Robert D.

In: Molecular Genetics and Metabolism, Vol. 83, No. 1-2, 09.2004, p. 175-183.

Research output: Contribution to journalArticle

Ginat, Sharon ; Battaile, Kevin P. ; Battaile, Brian C. ; Maslen, Cheryl ; Gibson, K. Michael ; Steiner, Robert D. / Lowered DHCR7 activity measured by ergosterol conversion in multiple cell types in Smith-Lemli-Opitz syndrome. In: Molecular Genetics and Metabolism. 2004 ; Vol. 83, No. 1-2. pp. 175-183.
@article{b60baaa5b89846c9a32fefe7c8827cf9,
title = "Lowered DHCR7 activity measured by ergosterol conversion in multiple cell types in Smith-Lemli-Opitz syndrome",
abstract = "Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder of cholesterol metabolism characterized by multiple congenital anomalies and mental retardation. SLOS results from mutations in 7-dehydrocholesterol Δ 7 reductase (DHCR7), the gene encoding the final enzyme involved in cholesterol biosynthesis. The resulting cholesterol deficiency and excessive 7- and 8-dehydrocholesterol (7-DHC, 8-DHC) in plasma and tissues are almost always diagnostic for SLOS. We measured DHCR7 activity in fibroblasts, amniocytes, and chorionic villi from controls, heterozygotes, and SLOS subjects. The enzyme activity (expressed as percent conversion of substrate) was significantly lower in untransformed fibroblasts from SLOS subjects (4.47{\%}±0.72) compared to untransformed fibroblasts from heterozygotes (26.6{\%}±4.6, p <0.01) or controls (50.6{\%}±5.3, p <0.001). We also measured plasma cholesterol and 7-DHC, determined the severity score and identified DHCR7 mutations for most of the subjects. There was no significant correlation of enzyme activity with severity score, plasma cholesterol level, plasma 7-DHC level, or the 7-DHC:cholesterol ratio. We conclude that even though enzyme activity as measured by the ergosterol assay may not correlate with severity, this assay has the potential to distinguish SLOS cells from carrier or unaffected cells in a variety of cell types, and should prove useful in confirming a diagnosis in atypical cases where sterol levels are equivocal. Additionally, it may be important to measure residual enzyme activity in SLOS subjects being considered for a trial of statins, as this treatment could theoretically be detrimental in subjects with little or no DHCR7 activity. Finally, the data suggest a threshold enzyme activity of 8{\%} conversion, below which disease occurs.",
keywords = "Cholesterol, DHCR7, Diagnosis, Enzyme assay, Metabolic disorder, Metabolism, Severity score, Smith-Lemli-Opitz",
author = "Sharon Ginat and Battaile, {Kevin P.} and Battaile, {Brian C.} and Cheryl Maslen and Gibson, {K. Michael} and Steiner, {Robert D.}",
year = "2004",
month = "9",
doi = "10.1016/j.ymgme.2004.07.002",
language = "English (US)",
volume = "83",
pages = "175--183",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - Lowered DHCR7 activity measured by ergosterol conversion in multiple cell types in Smith-Lemli-Opitz syndrome

AU - Ginat, Sharon

AU - Battaile, Kevin P.

AU - Battaile, Brian C.

AU - Maslen, Cheryl

AU - Gibson, K. Michael

AU - Steiner, Robert D.

PY - 2004/9

Y1 - 2004/9

N2 - Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder of cholesterol metabolism characterized by multiple congenital anomalies and mental retardation. SLOS results from mutations in 7-dehydrocholesterol Δ 7 reductase (DHCR7), the gene encoding the final enzyme involved in cholesterol biosynthesis. The resulting cholesterol deficiency and excessive 7- and 8-dehydrocholesterol (7-DHC, 8-DHC) in plasma and tissues are almost always diagnostic for SLOS. We measured DHCR7 activity in fibroblasts, amniocytes, and chorionic villi from controls, heterozygotes, and SLOS subjects. The enzyme activity (expressed as percent conversion of substrate) was significantly lower in untransformed fibroblasts from SLOS subjects (4.47%±0.72) compared to untransformed fibroblasts from heterozygotes (26.6%±4.6, p <0.01) or controls (50.6%±5.3, p <0.001). We also measured plasma cholesterol and 7-DHC, determined the severity score and identified DHCR7 mutations for most of the subjects. There was no significant correlation of enzyme activity with severity score, plasma cholesterol level, plasma 7-DHC level, or the 7-DHC:cholesterol ratio. We conclude that even though enzyme activity as measured by the ergosterol assay may not correlate with severity, this assay has the potential to distinguish SLOS cells from carrier or unaffected cells in a variety of cell types, and should prove useful in confirming a diagnosis in atypical cases where sterol levels are equivocal. Additionally, it may be important to measure residual enzyme activity in SLOS subjects being considered for a trial of statins, as this treatment could theoretically be detrimental in subjects with little or no DHCR7 activity. Finally, the data suggest a threshold enzyme activity of 8% conversion, below which disease occurs.

AB - Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder of cholesterol metabolism characterized by multiple congenital anomalies and mental retardation. SLOS results from mutations in 7-dehydrocholesterol Δ 7 reductase (DHCR7), the gene encoding the final enzyme involved in cholesterol biosynthesis. The resulting cholesterol deficiency and excessive 7- and 8-dehydrocholesterol (7-DHC, 8-DHC) in plasma and tissues are almost always diagnostic for SLOS. We measured DHCR7 activity in fibroblasts, amniocytes, and chorionic villi from controls, heterozygotes, and SLOS subjects. The enzyme activity (expressed as percent conversion of substrate) was significantly lower in untransformed fibroblasts from SLOS subjects (4.47%±0.72) compared to untransformed fibroblasts from heterozygotes (26.6%±4.6, p <0.01) or controls (50.6%±5.3, p <0.001). We also measured plasma cholesterol and 7-DHC, determined the severity score and identified DHCR7 mutations for most of the subjects. There was no significant correlation of enzyme activity with severity score, plasma cholesterol level, plasma 7-DHC level, or the 7-DHC:cholesterol ratio. We conclude that even though enzyme activity as measured by the ergosterol assay may not correlate with severity, this assay has the potential to distinguish SLOS cells from carrier or unaffected cells in a variety of cell types, and should prove useful in confirming a diagnosis in atypical cases where sterol levels are equivocal. Additionally, it may be important to measure residual enzyme activity in SLOS subjects being considered for a trial of statins, as this treatment could theoretically be detrimental in subjects with little or no DHCR7 activity. Finally, the data suggest a threshold enzyme activity of 8% conversion, below which disease occurs.

KW - Cholesterol

KW - DHCR7

KW - Diagnosis

KW - Enzyme assay

KW - Metabolic disorder

KW - Metabolism

KW - Severity score

KW - Smith-Lemli-Opitz

UR - http://www.scopus.com/inward/record.url?scp=4744353289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4744353289&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2004.07.002

DO - 10.1016/j.ymgme.2004.07.002

M3 - Article

VL - 83

SP - 175

EP - 183

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1-2

ER -